Table 2.

Incidence of adverse reactions occurring in ≥10% of patients with multiple myeloma treated with carfilzomib

Patients [N = 526 (%)]
EventsAll gradesaGrade 3Grade 4
Fatigue292 (56)38 (7)2 (<1)
Anemia246 (47)111 (21)7 (1)
Nausea236 (45)7 (1)0 (0)
Thrombocytopenia191 (36)69 (13)54 (10)
Dyspnea182 (35)25 (5)1 (<1)
Diarrhea172 (33)4 (<1)1 (<1)
Pyrexia160 (30)7 (1)2 (<1)
Upper respiratory tract infection149 (28)17 (3)0 (0)
Headache145 (28)7 (1)0 (0)
Cough137 (26)1 (<1)0 (0)
Blood creatinine increased127 (24)13 (3)1 (<1)
Lymphopenia126 (24)84 (16)11 (2)
Edema peripheral126 (24)3 (<1)0 (0)
Vomiting117 (22)5 (1)0 (0)
Constipation110 (21)1 (<1)0 (0)
Neutropenia109 (21)50 (10)4 (<1)
Back pain106 (20)15 (3)0 (0)
Insomnia94 (18)0 (0)0 (0)
Chills84 (16)1 (<1)0 (0)
Arthralgia83 (16)7 (1)0 (0)
Muscle spasms76 (14)2 (<1)0 (0)
Hypertension75 (14)15 (3)2 (<1)
Asthenia73 (14)12 (2)1 (<1)
Hypokalemia72 (14)14 (3)3 (<1)
Hypomagnesemia71 (14)2 (<1)0 (0)
Leukopenia71 (14)27 (5)1 (<1)
Pain in extremity70 (13)7 (1)0 (0)
Pneumonia67 (13)52 (10)3 (<1)
AST increased66 (13)15 (3)1 (<1)
Dizziness66 (13)5 (1)1 (<1)
Hypoesthesia64 (12)3 (<1)0 (0)
Anorexia63 (12)1 (<1)0 (0)
Pain63 (12)12 (2)1 (<1)
Hyperglycemia62 (12)16 (3)3 (<1)
Chest wall pain60 (11)3 (<1)0 (0)
Hypercalcemia58 (11)13 (3)8 (2)
Hypophosphatemia55 (11)24 (5)3 (<1)
Hyponatremia54 (10)31 (6)3 (<1)

Abbreviation: AST, aspartate aminotransferase.

  • aThe intensity of adverse reactions was determined using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 3.